Selected article for: "acute ards respiratory distress syndrome and low quality"
Author: Xiao, Kun; Hou, Fei; Huang, Xiuyu; Li, Binbin; Qian, Zhi Rong; Xie, Lixin
Title: Mesenchymal stem cells: current clinical progress in ARDS and COVID-19
  • Cord-id: 2zp2drd7
  • Document date: 2020_7_22
    • ID: 2zp2drd7
    Snippet: Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologicall
    Document: Acute respiratory distress syndrome (ARDS) develops rapidly and has a high mortality rate. Survivors usually have low quality of life. Current clinical management strategies are respiratory support and restricted fluid input, and there is no suggested pharmacological treatment. Mesenchymal stromal cells (MSCs) have been reported to be promising treatments for lung diseases. MSCs have been shown to have a number of protective effects in some animal models of ARDS by releasing soluble, biologically active factors. In this review, we will focus on clinical progress in the use of MSCs as a cell therapy for ARDS, which may have clinical implications during the coronavirus disease 2019 (COVID-19) pandemic.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • action mechanism and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and lung injury alleviate: 1, 2
    • action mechanism and lung injury model: 1, 2, 3
    • activation proliferation and acute ards respiratory distress syndrome: 1, 2
    • activation proliferation and acute respiratory distress syndrome: 1, 2, 3, 4
    • activation proliferation and lung edema: 1
    • activation proliferation and lung endothelial: 1, 2
    • activation proliferation and lung injury: 1, 2, 3
    • acute ards ali lung injury and lung affect: 1, 2
    • acute ards ali lung injury and lung edema: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute ards ali lung injury and lung endothelial: 1, 2, 3, 4, 5
    • acute ards ali lung injury and lung endothelial barrier: 1
    • acute ards ali lung injury and lung endothelial cell: 1
    • acute ards ali lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards ali lung injury and lung injury model: 1, 2
    • acute ards ali lung injury treatment and lung injury: 1, 2, 3
    • acute ards respiratory distress syndrome and lung affect: 1, 2, 3, 4, 5, 6